-
1.
公开(公告)号:WO2022038636A1
公开(公告)日:2022-02-24
申请号:PCT/IN2021/050793
申请日:2021-08-17
发明人: SINGH, Gyanendra , BISWAS, Souvik , PAL, Arijit , GHOSH, Nilanjana , BHATTACHARYYA, Parthasarathi , CHAUDHURY, Koel
摘要: The present invention provides a device and method for differentiating Asthma-COPD Overlap (ACO) from Asthma and COPD. SAM layer formed on gold electrodes is characterized in the experimental set up. The mounting of antibody on activated gold electrode is confirmed through various assays. The fabrication of the device is standardized for reproducibility of the data with IL-4 Antibody.
-
公开(公告)号:WO2020144714A1
公开(公告)日:2020-07-16
申请号:PCT/IN2020/050031
申请日:2020-01-10
IPC分类号: A61B34/30
摘要: The present disclosure relates to a robotic system (100) used for performing minimally invasive surgery. The robotic system (100) comprises a first actuator (104-1), a second actuator (106-1), a third actuator (110-1) and a tool (116). The second actuator (106-1) is connected with the first actuator (104-1) configured to move the second actuator (106-1) about a first axis (X). The third actuator (110-1) is connected with the second actuator (106-1) configured to move the third actuator (110-1) about a second axis (Y) orthogonal to the first axis (X). The third actuator (110-1) is configured to move a tool (116) along a third axis (Z) orthogonal to the second axis (Y) and first axis (X). The robotic system (100) further comprises at least one compliant RCM mechanism (104-2, 106-2) configured to connect the first actuator (104-1) to the second actuator (106-1) and, the second actuator (106-1) to the third actuator (110-1).
-
3.
公开(公告)号:WO2019035141A1
公开(公告)日:2019-02-21
申请号:PCT/IN2018/050312
申请日:2018-05-17
发明人: CHHIBBER, Sanjay , KATARE, O.p , CHADHA, Parul
IPC分类号: C12N7/00
CPC分类号: A61K35/76 , C12N7/00 , C12N2795/00032
摘要: A phage cocktail composition comprises of five different strains of bacteriophages alongwith phosphotidylcholine (PC), tween 80 and stearylamaine.
-
4.
公开(公告)号:WO2018179003A9
公开(公告)日:2018-10-04
申请号:PCT/IN2018/050158
申请日:2018-03-21
IPC分类号: A61K39/112
摘要: A novel consortium used as potent vaccine for treating of enteric fever, comprised of isolated Outer Membrane Vesicles (OMVs) taken from two different strains of typhoidal Salmonella species.
-
公开(公告)号:WO2015001570A1
公开(公告)日:2015-01-08
申请号:PCT/IN2014/000441
申请日:2014-07-02
发明人: PARASHAR, DEEPTI , ARANKALLE, A. , VIDYA , PAINGANKAR, S., MANDAR , KUMAR, SATYENDRA , GOKHALE, D., MANGESH , SUDEEP, B., A. , SHINDE, S., SAPNA
IPC分类号: C12N15/113 , A61P31/14 , A61K31/713
CPC分类号: C12N15/1131 , A61K31/713 , C12N2310/14 , C12N2320/30
摘要: The present invention relates to RNAi agents for inhibition of Chikungunya virus are described herein. The present invention provides RNAi agents for inhibition of Chikungunya virus, particularly by targeting the E2 gene and nsPl gene or both of the Chikungunya virus; the RNAi agents comprising of the entire nucleotide sequence set forth is SEQ ID 1 or SEQ ID 5 or combination thereof; or comprising of 15 or more contiguous nucleotides as set forth is SEQ ID 1 or SEQ ID 5 or combination thereof along with the addition nucleotides from the contiguous region of the E2 and nsPl target gene. The invention further provides a RNAi composition for reducing the E2 protein and nsPl protein level of Chikungunya virus and inhibition of Chikungunya virus replication. The combination of RNAi agents provides an excellent therapeutic composition for treatment of Chikungunya virus infection.
摘要翻译: 本发明涉及用于抑制基孔肯雅病毒的RNAi剂。 本发明提供用于抑制基孔肯雅病毒的RNAi试剂,特别是通过靶向E2基因和nsP1基因或两者基孔肯雅病毒; 包含所述全部核苷酸序列的RNAi试剂是SEQ ID 1或SEQ ID 5或其组合; 或包含15个或更多个连续核苷酸,如SEQ ID 1或SEQ ID 5或其组合以及来自E2和nsP1靶基因的连续区域的加成核苷酸。 本发明还提供了用于降低基孔肯雅病毒的E2蛋白和nsP1蛋白水平的RNAi组合物,并抑制基孔肯雅病毒复制。 RNAi剂的组合提供了治疗基孔肯雅病毒感染的极好的治疗组合物。
-
公开(公告)号:WO2023002505A1
公开(公告)日:2023-01-26
申请号:PCT/IN2022/050649
申请日:2022-07-19
IPC分类号: C12Q1/68 , C12Q1/70 , A61K39/215
摘要: The present invention relates to novel oligonucleotide sequences for rapid screening of epidemiologically important variants of SARS-CoV-2, wherein said oligonucleotide sequences acts as primers for amplification of sequences having Single-nucleotide polymorphisms (SNP)/mutations in the spike glycoprotein gene. The invention also relates to an assay for rapid screening of epidemiologically important variants of SARS-CoV-2 based upon using novel oligonucleotide sequences as primers. In particular, invention relates to oligonucleotide sequences of SEQ ID Nos. 1 – 37 for rapid screening of epidemiologically important variants of SARS-CoV-2.
-
公开(公告)号:WO2021245708A1
公开(公告)日:2021-12-09
申请号:PCT/IN2021/050549
申请日:2021-06-05
发明人: NANDI, Shyam Sundar , LAMBE, Upendra Pradeep , SAWANT, Sonali Ankush , GOHIL, Trupti Shashikant , DESHPANDE, Jagadish Mohan
摘要: The present invention provides a rapid and sensitive method for detecting SARS-CoV-2. More particularly, the present invention provides a method comprising the steps: (i) providing a biological sample and extracting RNA; (ii) adding RNA sample of step (i) to a set of loop-mediated isothermal amplification (LAMP) primers specific for genes selected from envelope protein (E), membrane glycoprotein (M), spike glycoprotein (S), nucleocapsid protein (N) and RNA dependent RNA polymerase (RdRp); wherein the set of primers are selected from the group consisting of SEQ ID NOs: 1-50; (iii) incubating the sample of step (ii) with a colorimetric LAMP reagent in a reaction mixture at a temperature 65ºC for 30 minutes; and (iv) obtaining a visual change in the reaction mixture. The present method is specific and results can be observed by naked eyes.
-
8.
公开(公告)号:WO2020053897A1
公开(公告)日:2020-03-19
申请号:PCT/IN2019/050671
申请日:2019-09-13
摘要: The present invention provides a modified polio virus receptor (PVR/CD155) gene. Said gene comprises one or more mutations in exons selected from exons 2, 3 and 4 of poliovirus receptor (PVR/CD155) gene having SEQ ID No.1. More specifically, the present invention provides cell lines comprising said modified gene and method of producing the same using clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (CRISPR-Cas9) system. The said cell line is refractory (non-permissive) to poliovirus and susceptible to most enteroviruses and many other human viruses. Further, use of said cell line is research, diagnostic and therapy.
-
9.
公开(公告)号:WO2019016826A1
公开(公告)日:2019-01-24
申请号:PCT/IN2018/050450
申请日:2018-07-10
申请人: GURU GHASIDAS VISHWAVIDYALAYA (A CENTRAL UNIVERSITY) , INDIAN COUNCIL OF MEDICAL RESEARCH (ICMR)
IPC分类号: A61K31/00 , A61K31/426 , C07D277/10
CPC分类号: C07D277/34 , A61K45/06
摘要: Disclosed are novel 5-[4-(2-biphenyl-4-yl-2-oxo-ethoxy)-benzylidene]-thiazolidine-2,4-dione compounds of general formula (I), their pharmaceutically acceptable salts, solvates their synthesis and uses thereof, to pharmaceutical compositions containing compounds and to the use of such compounds and composition in medicines either alone or in combination with other compounds.
-
公开(公告)号:WO2016132377A1
公开(公告)日:2016-08-25
申请号:PCT/IN2016/000040
申请日:2016-02-09
发明人: DAS, SANTASABUJ , BHUNIA, ANIRBUN
IPC分类号: C07K7/06
摘要: A peptide to neutralize lipopolysaccharide molecule comprising an amino acid sequence set forth in sequence ID 2. A peptide that could be a prime target for pharmacological intervention towards development of effective anti- sepsis drugs.
摘要翻译: 用于中和包含序列ID 2所示的氨基酸序列的脂多糖分子的肽。可以作为用于开发有效抗脓毒症药物的药物干预的主要靶标的肽。
-
-
-
-
-
-
-
-
-